Episode 43 – Does Allergen Immunotherapy Improve Anti-viral Immunity?

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Sarah Spriet, DO, an allergist/immunologist at the Alexander T. Augusta Military Medical Center in Fort Belvoir, VA and an assistant editor of Allergy Watch. We will be reviewing the November-December 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial.  Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.  Prevalence of CFTR variants in primary immunodeficiency patients with bronchiectasis is an important modifying cofactor. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: [email protected] ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Drs. Lee and Spriet have nothing to disclose Dr. Fineman: Research: DBV, Novartis, Alladapt